Interventions for central serous chorioretinopathy: a network meta‐analysis
A review of 67 RCTs on Central Serous Chorioretinopathy (CSC) found no single treatment definitively superior. While low-dose photodynamic therapy, supplements, and eplerenone showed potential for improving vision, the evidence is limited by small, poorly reported trials and low confidence in findings, highlighting a need for larger, high-quality research.
Central serous chorioretinopathy (CSC) is characterised by a thickened and dysfunctional choroid, which is accompanied by a serous detachment of the neural retina. The effects on the retina are usually self‐limiting, although some people are left with irreversible vision loss due to progressive and permanent photoreceptor damage or atrophy of the retinal pigment epithelium (RPE).
Click here to access the article.